Seed Therapeutics

Seed Therapeutics is a global research company dedicated to discovering and developing molecular glues, a novel class of drugs that target previously undruggable proteins. Their mission is to address the world's most debilitating diseases and disorders, including cancer, neurodegeneration, and infectious diseases. Seed Therapeutics boasts a team of world-leading experts in the Ubiquitin Proteasome System and Targeted Protein Degradation, and they are actively advancing a groundbreaking discovery platform.

Seed Therapeutics has secured significant funding through collaborations and investments, including those from Eli Lilly, BeyondSpring, and Eisai. They are progressing multiple pipeline programs across key therapeutic indications and have achieved several milestones, such as the successful discovery of an RBM39 degrader that has reached IND Candidate status. With their focus on the development of oral molecular glues, Seed Therapeutics is well-positioned to advance high-profile programs into clinical trials and create value for patients and shareholders.

Seed Therapeutics is a global research company dedicated to revolutionizing the treatment of debilitating diseases by developing novel Molecular Glues. Their mission is to overcome scientific barriers and discover these glues, which target previously “undruggable” proteins, ultimately leading to effective therapies and cures. This is achieved through their groundbreaking discovery platform and collaboration with a team of world-leading experts in the Ubiquitin Proteasome System and Targeted Protein Degradation.

Seed Therapeutics fosters a culture of innovation and collaboration, emphasizing scientific excellence and a commitment to positively impacting human health. The company values the expertise of its world-leading team of scientists and embraces a collaborative approach to research and development. Their focus on tackling previously undruggable targets demonstrates a bold and ambitious spirit, while their partnerships with industry giants like Eli Lilly and Eisai reflect a commitment to pushing the boundaries of scientific discovery.